Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Thyroid Eye Disease: full-pipeline trial registry
5 of 16 indexed Thyroid Eye Disease trials are currently recruiting.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 5 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Thyroid Eye Disease: 16 US clinical trials tracked, 5 recruiting.
Thyroid Eye Disease is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Viridian Therapeutics, running 4 of these trials.
Enrollment posture brief
Registry condition thyroid-eye-disease
OPEN 5 | RECR 31% | LATE 9 | EARLY 6 | RANK #1060 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Aortic Valve Disease (31% recruiting · 16 trials)
Thyroid Eye Disease lists 5 open slots (31% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Thyroid Eye Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Thyroid Eye Disease is recruiting below its size-band peers.
5 of 16 indexed trials (31.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Thyroid Eye Disease research.
Viridian Therapeutics accounts for 4 of 16 trials (25%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Thyroid Eye Disease enrolment sits around 100 participants.
Median target enrolment is 100 among the 16 trials that report a genuine target (sentinel values excluded). 8 of those (50%) plan for fewer than 100 participants.
-
Thyroid Eye Disease research is mostly interventional.
15 interventional and 1 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Walter Reed National Military Medical Center
NCT06275373
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
Amgen
NCT06401044
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
Tourmaline Bio
NCT06088979
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sling Therapeutics
NCT06112340
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
Peter Timoney
NCT06467435
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
Viridian Therapeutics
NCT06625398
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
Immunovant Sciences
NCT05517447
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Hoffmann-La Roche
NCT05987423
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Hoffmann-La Roche
NCT06106828
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
Viridian Therapeutics
NCT06625411
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Immunovant Sciences
NCT05524571
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sling Therapeutics
NCT05276063
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
Amgen
NCT06248619
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
Viridian Therapeutics
NCT07155668
A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )
Viridian Therapeutics
NCT05176639
Anti-VEGF Therapy for Acute Thyroid Eye Disease
Massachusetts Eye and Ear Infirmary
NCT04311606
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Thyroid Eye Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Thyroid Eye Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Thyroid Eye Disease page
16 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Thyroid Eye Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Viridian Therapeutics sponsors the most Thyroid Eye Disease trials on record, review their full trial history before evaluating a specific study. See Viridian Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Thyroid Eye Disease condition card totals 16 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.